HRP970362A2 - Method for treating and preventing neurodegenerative disorders - Google Patents

Method for treating and preventing neurodegenerative disorders

Info

Publication number
HRP970362A2
HRP970362A2 HR60/021,571A HRP970362A HRP970362A2 HR P970362 A2 HRP970362 A2 HR P970362A2 HR P970362 A HRP970362 A HR P970362A HR P970362 A2 HRP970362 A2 HR P970362A2
Authority
HR
Croatia
Prior art keywords
pct
treating
neurodegenerative disorders
preventing neurodegenerative
sec
Prior art date
Application number
HR60/021,571A
Other languages
English (en)
Inventor
Richard Thomas Carroll
Richard Dennis Dyer
Lillian Jane Robichaud
Brenda De Rae Shivers
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HRP970362A2 publication Critical patent/HRP970362A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
HR60/021,571A 1996-07-11 1997-07-03 Method for treating and preventing neurodegenerative disorders HRP970362A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2157196P 1996-07-11 1996-07-11

Publications (1)

Publication Number Publication Date
HRP970362A2 true HRP970362A2 (en) 1998-04-30

Family

ID=21804973

Family Applications (1)

Application Number Title Priority Date Filing Date
HR60/021,571A HRP970362A2 (en) 1996-07-11 1997-07-03 Method for treating and preventing neurodegenerative disorders

Country Status (23)

Country Link
US (1) US5912259A (zh)
EP (1) EP0914122B1 (zh)
JP (1) JP2001508028A (zh)
KR (1) KR20000023683A (zh)
CN (1) CN1145481C (zh)
AT (1) ATE250416T1 (zh)
AU (1) AU726664B2 (zh)
BR (1) BR9710467A (zh)
CA (1) CA2255073A1 (zh)
CO (1) CO4940509A1 (zh)
DE (1) DE69725147T2 (zh)
DK (1) DK0914122T3 (zh)
ES (1) ES2205247T3 (zh)
HK (1) HK1020533A1 (zh)
HR (1) HRP970362A2 (zh)
IL (1) IL127487A (zh)
NO (1) NO990076L (zh)
NZ (1) NZ332763A (zh)
PL (1) PL331049A1 (zh)
PT (1) PT914122E (zh)
TR (1) TR199900040T2 (zh)
WO (1) WO1998002160A1 (zh)
ZA (1) ZA976142B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003247514A1 (en) * 2002-06-11 2003-12-22 Roy Ogle Meningeal-derived stem cells
US20110104296A1 (en) * 2008-05-08 2011-05-05 Dipak Kumar Sarkar Endorphin Therapy Compositions and Methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79648A (en) * 1985-08-09 1991-12-12 Lilly Co Eli Pharmaceutical anti-inflammatory and ischemia preventing compositions containing di-t-butylphenol derivatives,some such novel compounds and process for their preparation
DK0391644T3 (da) * 1989-04-07 1996-07-15 Lilly Co Eli Arylsubstituerede rhodaninderivater
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
EP0915090A1 (en) * 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
WO1996022772A1 (en) * 1995-01-23 1996-08-01 Eli Lilly And Company Method for treating multiple sclerosis
ES2247604T3 (es) * 1995-06-12 2006-03-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.

Also Published As

Publication number Publication date
KR20000023683A (ko) 2000-04-25
PL331049A1 (en) 1999-06-21
US5912259A (en) 1999-06-15
NZ332763A (en) 2000-07-28
ATE250416T1 (de) 2003-10-15
CN1223582A (zh) 1999-07-21
CO4940509A1 (es) 2000-07-24
PT914122E (pt) 2003-12-31
JP2001508028A (ja) 2001-06-19
AU726664B2 (en) 2000-11-16
CN1145481C (zh) 2004-04-14
NO990076D0 (no) 1999-01-08
NO990076L (no) 1999-01-08
AU3649197A (en) 1998-02-09
HK1020533A1 (en) 2000-05-12
IL127487A (en) 2002-04-21
DE69725147T2 (de) 2004-07-22
ZA976142B (en) 1998-02-02
CA2255073A1 (en) 1998-01-22
ES2205247T3 (es) 2004-05-01
TR199900040T2 (xx) 1999-04-21
DK0914122T3 (da) 2003-12-22
IL127487A0 (en) 1999-10-28
EP0914122A1 (en) 1999-05-12
EP0914122B1 (en) 2003-09-24
DE69725147D1 (de) 2003-10-30
WO1998002160A1 (en) 1998-01-22
BR9710467A (pt) 1999-08-17

Similar Documents

Publication Publication Date Title
EP0604433A4 (en) Composition and method for disease treatment.
BG103646A (en) Arylsulphonamides, their analogues and application for the treatment of neurodegenerative diseases
ZA972200B (en) Novel bridged cyclic amino acids as pharmaceutical agents.
ZA972199B (en) Novel bridged cyclic amino acids as pharmaceutical agents.
IL128416A0 (en) Pharmaceutical composition for the treatment of alzheimer's disease
CA2168829A1 (en) Paroxetine hydrochloride anhydrate forms a,b,c and d
WO1999045011A8 (en) Glycine transport inhibitors
AU616127B2 (en) A method of treating anxiety related disorders using sertraline
BG104685A (en) Glycine transport inhibitors
EP0871496A4 (zh)
ZA9711279B (en) Method for treating and preventing neurological disorders and promoting wound healing.
AUPP674898A0 (en) A method of treatment
GEP20032914B (en) Derivatives of 1,3,4-Oxadiazolone
DE59608804D1 (en) (s)-hydroxynitrillyase aus hevea brasiliensis
HRP970362A2 (en) Method for treating and preventing neurodegenerative disorders
TW285640B (zh)
ZA964198B (en) Treatment regime for skin.
EP1447090B8 (de) Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen
WO1994025012A3 (en) Medicaments for treatment of migraine, epilepsy and feeding disorders
AU6053496A (en) The use of sertraline to treat post myocardial infarction patients
CA2158173A1 (en) Method of treating addictive behaviors
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
KR19987002519A (en) Process for subsequent codensation of polycondensates , in particular of poyamide 6.6
Pinnegar Men, masculinities and feminist theory: having a gender too.
AU1209501A (en) Method for treating parkinson's disease by administering (-)-5-keto-2-n,n-di-n-propylamino-tetrahydrotetralin

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20040705

Year of fee payment: 8

ODBI Application refused